UBS AM’s Flexion Therapeutics, Inc. FLXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-60,406
| Closed | -$368K | – | 2945 |
|
|
2021
Q3 | $368K | Hold |
60,406
| – | – | ﹤0.01% | 2584 |
|
|
2021
Q2 | $497K | Buy |
60,406
+12,222
| +25% | +$104K | ﹤0.01% | 2541 |
|
|
2021
Q1 | $431K | Buy |
48,184
+1,660
| +4% | +$19K | ﹤0.01% | 2431 |
|
|
2020
Q4 | $537K | Hold |
46,524
| – | – | ﹤0.01% | 2276 |
|
|
2020
Q3 | $484K | Buy |
46,524
+5,092
| +12% | +$62.4K | ﹤0.01% | 2159 |
|
|
2020
Q2 | $545K | Buy |
41,432
+4,513
| +12% | +$46.8K | ﹤0.01% | 2090 |
|
|
2020
Q1 | $291K | Sell |
36,919
-5,229
| -12% | -$78.8K | ﹤0.01% | 2166 |
|
|
2019
Q4 | $872K | Buy |
42,148
+19,220
| +84% | +$324K | ﹤0.01% | 1980 |
|
|
2019
Q3 | $314K | Buy |
22,928
+12,770
| +126% | +$152K | ﹤0.01% | 2442 |
|
|
2019
Q2 | $125K | Hold |
10,158
| – | – | ﹤0.01% | 2621 |
|
|
2019
Q1 | $127K | Buy |
+10,158
| New | +$136K | ﹤0.01% | 2547 |
|
UBS AM's FLXN Position: Q4 2021 in Review
UBS AM sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 60,406 shares — an estimated $368K sold.
UBS AM first reported a position in FLXN in Q1 2019 and held it in 11 quarters. The position peaked at $872K in Q4 2019. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.
- UBS AM reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- UBS AM sold 60,406 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $368K.
- UBS AM first reported a position in Flexion Therapeutics, Inc. in Q1 2019 and held it in 11 quarters.
- UBS AM's Flexion Therapeutics, Inc. position peaked at $872K in Q4 2019.
- 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.
Based on UBS AM's 13F filing for Q4 2021, filed 14 Feb 2022.